Health
STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
Publication: STAT
Author: Ed Silverman
Source published: 17/11/2026, 14:25:41 UTC
Briefing created: 17/11/2026, 16:05:47 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 14:36:24 UTC.
Briefings
The U.S. FDA approved Roche's giredestrant, a new breast cancer drug, marking a significant regulatory milestone for the company. Simultaneously, a clinical trial at Obesity Week found that semaglutide (Ozempic/Wegovy) significantly reduces obesity in children aged 6-11, with nearly 40% achieving weight loss after 68 weeks. The article notes Roche's historical struggles in oncology but highlights the potential for giredestrant to become a top-selling product. Key facts include the drug's approval status, the specific age range of the pediatric trial, and the weight loss percentage. The source is a blog post from STAT+ dated November 17, 2026, which serves as the primary evidence for these findings.
Key points
- The U.S. FDA approved Roche's giredestrant, a new breast cancer drug, which the company aims to become its top-selling product.
- A clinical trial at Obesity Week showed that semaglutide significantly reduces obesity in children aged 6 to 11, with nearly 40% achieving weight loss after 68 weeks.
Context
STAT+ is a blog post from November 17, 2026, reporting on FDA approvals and clinical trials. The article discusses Roche's history with oncology drugs and the potential impact of giredestrant. The pediatric study details the effectiveness of semaglutide in obese children, though it notes some doctors are cautious about prescribing it to this age group.
Limitations
The evidence is limited to a single blog post from STAT+ dated November 17, 2026. The source does not provide additional background on regulatory processes, patient demographics beyond the 6-11 age range, or long-term safety data. The clinical trial results are presented as observed facts from the study, but the source does not offer independent verification or further validation of the findings.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 17/11/2026, 16:05:47 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidibaf2tpydcckhuqfsleauzl6qyimhn5onciqxg3qqxdr4e4lhpa